Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Coronary Heart Disease

Not Applicable
Withdrawn
Conditions
Interventions
First Posted Date
2020-03-16
Last Posted Date
2024-11-20
Lead Sponsor
Henan Institute of Cardiovascular Epidemiology
Target Recruit Count
594
Registration Number
NCT04308551

A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients

First Posted Date
2020-03-13
Last Posted Date
2024-04-22
Lead Sponsor
Shanghai Tong Ren Hospital
Target Recruit Count
40
Registration Number
NCT04307511
Locations
🇨🇳

shanghai Tongren hospital, Shanghai, China

Influence of Rivaroxaban for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic PAD

Not yet recruiting
Conditions
Interventions
First Posted Date
2020-03-12
Last Posted Date
2021-03-10
Lead Sponsor
Poznan University of Medical Sciences
Target Recruit Count
100
Registration Number
NCT04305028

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2020-03-04
Last Posted Date
2024-10-04
Lead Sponsor
University of Miami
Target Recruit Count
5478
Registration Number
NCT04295486
Locations
🇺🇸

University of Miami Hospital, Miami, Florida, United States

Personalizing Aspirin Therapy in Peripheral Arterial Disease Patients

Not Applicable
Conditions
Interventions
First Posted Date
2020-02-17
Last Posted Date
2020-10-26
Lead Sponsor
Unity Health Toronto
Target Recruit Count
150
Registration Number
NCT04269863

Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

First Posted Date
2020-01-27
Last Posted Date
2024-06-18
Lead Sponsor
Fu Wai Hospital, Beijing, China
Target Recruit Count
1220
Registration Number
NCT04240834
Locations
🇨🇳

Fuwai Hospital, Beijing, Beijing, China

Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.

First Posted Date
2020-01-18
Last Posted Date
2021-04-20
Lead Sponsor
Science Valley Research Institute
Target Recruit Count
200
Registration Number
NCT04229264
Locations
🇧🇷

IAMSPE - Sao Paulo Public Servants Hospital, São Paulo, Brazil

A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2019-12-05
Last Posted Date
2023-05-17
Lead Sponsor
The Christie NHS Foundation Trust
Target Recruit Count
42
Registration Number
NCT04188119

Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis

First Posted Date
2019-10-30
Last Posted Date
2024-01-22
Lead Sponsor
ANRS, Emerging Infectious Diseases
Target Recruit Count
768
Registration Number
NCT04145258
Locations
🇺🇬

Mbarara Regional Reference Hospital, Mbarara, Uganda

🇺🇬

Regional Reference Hospital of Kabale, Mbarara, Uganda

🇨🇮

Treichville University Hospital, Abidjan, Côte D'Ivoire

and more 10 locations

Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke

First Posted Date
2019-10-29
Last Posted Date
2019-10-29
Lead Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Target Recruit Count
60
Registration Number
NCT04142151
Locations
🇨🇳

Zhenguo Liu, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath